期刊
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
卷 25, 期 -, 页码 61-66出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ctro.2020.09.006
关键词
Non-small cell lung cancer; Sequential chemoradiotherapy; DNA damage repair inhibitor; Platform trial; Continual reassessment method
资金
- Cancer Research UK [A28890]
- Yorkshire Cancer Research
- NIHR Manchester Biomedical Research Centre
- MRC [MC_PC_12006, MC_UU_00001/6] Funding Source: UKRI
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding. (c) 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/ 4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据